New Risk • May 13
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 52% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Large one-off items impacting financial results. Shareholders have been diluted in the past year (23% increase in shares outstanding). New Risk • May 12
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 116% The company is paying a dividend despite having no free cash flows. Dividend yield: 0.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 116% Paying a dividend despite having no free cash flows. Minor Risk Shareholders have been diluted in the past year (23% increase in shares outstanding). Announcement • Apr 23
Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 15, 2026 Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 15, 2026, at 14:00 China Standard Time. Location: 5F, Building 28, Lane 908, Ziping Road, Pudong New Area, Shanghai China Announcement • Mar 30
Shanghai OPM Biosciences Co., Ltd. to Report Q1, 2026 Results on Apr 23, 2026 Shanghai OPM Biosciences Co., Ltd. announced that they will report Q1, 2026 results on Apr 23, 2026 Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: EPS: CN¥0.37 (up from CN¥0.19 in FY 2024). Revenue: CN¥354.9m (up 19% from FY 2024). Net income: CN¥41.7m (up 98% from FY 2024). Profit margin: 12% (up from 7.1% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 42%. Revenue is forecast to grow 21% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. New Risk • Feb 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (258% cash payout ratio). Shareholders have been diluted in the past year (16% increase in shares outstanding). Announcement • Dec 26
Shanghai OPM Biosciences Co., Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026 Shanghai OPM Biosciences Co., Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.11 (vs CN¥0.028 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.11 (up from CN¥0.028 in 3Q 2024). Revenue: CN¥93.8m (up 30% from 3Q 2024). Net income: CN¥11.9m (up 284% from 3Q 2024). Profit margin: 13% (up from 4.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Shanghai OPM Biosciences Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Shanghai OPM Biosciences Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.04 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.20 (up from CN¥0.04 in 2Q 2024). Revenue: CN¥94.1m (up 47% from 2Q 2024). Net income: CN¥22.9m (up 402% from 2Q 2024). Profit margin: 24% (up from 7.1% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in China. New Risk • Jul 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 287% Dividend per share is over 14x cash flows per share. Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Profit margins are more than 30% lower than last year (5.4% net profit margin). Announcement • Jun 30
Shanghai OPM Biosciences Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Shanghai OPM Biosciences Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Reported Earnings • Apr 16
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.19 (down from CN¥0.47 in FY 2023). Revenue: CN¥297.2m (up 22% from FY 2023). Net income: CN¥21.1m (down 61% from FY 2023). Profit margin: 7.1% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) also missed analyst estimates by 59%. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Announcement • Apr 16
Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 09, 2025 Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 09, 2025, at 14:00 China Standard Time. Location: 5F, Building 28, Lane 908, Ziping Road, Pudong New Area, Shanghai China Announcement • Mar 28
Shanghai OPM Biosciences Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Shanghai OPM Biosciences Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 02
Full year 2024 earnings released: EPS: CN¥0.19 (vs CN¥0.47 in FY 2023) Full year 2024 results: EPS: CN¥0.19 (down from CN¥0.47 in FY 2023). Revenue: CN¥297.2m (up 22% from FY 2023). Net income: CN¥21.1m (down 61% from FY 2023). Profit margin: 7.1% (down from 22% in FY 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 27% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Biotechs industry in China. Board Change • Feb 10
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Supervisor Jiangfeng Li was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Jan 17
Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) signed a letter of intent to acquire an unknown minority stake in PharmaLegacy Laboratories (Shanghai) Co., Ltd. from PharmaLegacy Hong Kong Limited, Jiaxing Hetuo Enterprise Management Partnership (Limited Partnership) and Jiaxing Huituo Enterprise Management Partnership (Limited Partnership). Shanghai OPM Biosciences Co., Ltd. (SHSE:688293) signed a letter of intent to acquire an unknown minority stake in PharmaLegacy Laboratories (Shanghai) Co., Ltd. from PharmaLegacy Hong Kong Limited, Jiaxing Hetuo Enterprise Management Partnership (Limited Partnership) and Jiaxing Huituo Enterprise Management Partnership (Limited Partnership) on January 16, 2025. Announcement • Dec 27
Shanghai OPM Biosciences Co., Ltd. to Report Fiscal Year 2024 Results on Apr 16, 2025 Shanghai OPM Biosciences Co., Ltd. announced that they will report fiscal year 2024 results on Apr 16, 2025 New Risk • Nov 14
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 136% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (13% net profit margin). Buy Or Sell Opportunity • Oct 31
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 30% to CN¥38.51. The fair value is estimated to be CN¥31.39, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.5% over the last 3 years. Earnings per share has declined by 35%. Revenue is forecast to grow by 118% in 2 years. Earnings are forecast to grow by 386% in the next 2 years. Announcement • Sep 30
Shanghai OPM Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Shanghai OPM Biosciences Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥33.42, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 32% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥48.74 per share. Announcement • Jun 28
Shanghai OPM Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024 Shanghai OPM Biosciences Co., Ltd. announced that they will report first half, 2024 results on Aug 27, 2024 Price Target Changed • Jun 13
Price target decreased by 8.9% to CN¥53.41 Down from CN¥58.66, the current price target is provided by 1 analyst. New target price is 39% above last closing price of CN¥38.56. Stock is down 18% over the past year. The company is forecast to post earnings per share of CN¥0.78 for next year compared to CN¥0.47 last year. New Risk • May 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 102% Paying a dividend despite having no free cash flows. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (19% net profit margin). Announcement • Apr 30
Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 20, 2024 Shanghai OPM Biosciences Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Shanghai China Reported Earnings • Apr 29
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥0.47 (down from CN¥1.10 in FY 2022). Revenue: CN¥243.1m (down 17% from FY 2022). Net income: CN¥54.0m (down 49% from FY 2022). Profit margin: 22% (down from 36% in FY 2022). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 39% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥30.10, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 22x in the Biotechs industry in China. Total loss to shareholders of 62% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥53.58 per share. Announcement • Mar 30
Shanghai OPM Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Shanghai OPM Biosciences Co., Ltd. announced that they will report Q1, 2024 results on Apr 29, 2024 Buy Or Sell Opportunity • Mar 07
Now 25% undervalued after recent price drop Over the last 90 days, the stock has fallen 33% to CN¥40.15. The fair value is estimated to be CN¥53.30, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 15% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 131% in 2 years. Earnings are forecast to grow by 268% in the next 2 years. Reported Earnings • Feb 28
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: CN¥0.47 (down from CN¥1.10 in FY 2022). Revenue: CN¥243.1m (down 17% from FY 2022). Net income: CN¥54.0m (down 49% from FY 2022). Profit margin: 22% (down from 36% in FY 2022). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 14%. Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 22% growth forecast for the Biotechs industry in China. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥40.95, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 21x in the Biotechs industry in China. Total loss to shareholders of 51% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥54.24 per share. Buy Or Sell Opportunity • Jan 29
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 26% to CN¥40.92. The fair value is estimated to be CN¥51.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 23%. Revenue is forecast to grow by 112% in 2 years. Earnings are forecast to grow by 170% in the next 2 years. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.31 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.002 (down from CN¥0.31 in 3Q 2022). Revenue: CN¥50.4m (down 34% from 3Q 2022). Net income: CN¥5.30m (down 82% from 3Q 2022). Profit margin: 11% (down from 39% in 3Q 2022). Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥54.97, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 40x in the Biotechs industry in China. Total loss to shareholders of 36% over the past year. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.77 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.12 (down from CN¥0.77 in 2Q 2022). Revenue: CN¥53.3m (down 28% from 2Q 2022). Net income: CN¥13.7m (down 51% from 2Q 2022). Profit margin: 26% (down from 38% in 2Q 2022). Announcement • Jun 28
Shanghai OPM Biosciences Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Shanghai OPM Biosciences Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Valuation Update With 7 Day Price Move • May 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥84.11, the stock trades at a trailing P/E ratio of 66.1x. Average trailing P/E is 43x in the Biotechs industry in China. Reported Earnings • Mar 30
Full year 2022 earnings released: EPS: CN¥1.54 (vs CN¥0.98 in FY 2021) Full year 2022 results: EPS: CN¥1.54 (up from CN¥0.98 in FY 2021). Revenue: CN¥294.4m (up 38% from FY 2021). Net income: CN¥105.4m (up 75% from FY 2021). Profit margin: 36% (up from 28% in FY 2021). The increase in margin was driven by higher revenue. Board Change • Nov 16
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Director Xia Cao is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 27
Third quarter 2022 earnings released: EPS: CN¥0.43 (vs CN¥0.23 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.43 (up from CN¥0.23 in 3Q 2021). Revenue: CN¥76.4m (up 24% from 3Q 2021). Net income: CN¥29.7m (up 109% from 3Q 2021). Profit margin: 39% (up from 23% in 3Q 2021). The increase in margin was primarily driven by higher revenue. Announcement • Sep 02
Shanghai OPM Biosciences Co., Ltd. has completed an IPO in the amount of CNY 1.643706 billion. Shanghai OPM Biosciences Co., Ltd. has completed an IPO in the amount of CNY 1.643706 billion.
Security Name: A Shares
Security Type: Common Stock
Securities Offered: 5,226,000
Price\Range: CNY 80.2
Discount Per Security: CNY 5.614
Security Name: A Shares
Security Type: Common Stock
Securities Offered: 15,269,082
Price\Range: CNY 80.2
Discount Per Security: CNY 5.614
Transaction Features: Sponsor Backed Offering